Table 1. Results of multivariate survival analyses.

Multivariate analysis of overall survival in the MI-All-AML cohort (middle column) and MI-dnAML cohort (right column). Models using age- and aCNA/cnLOH-based risk factors along with gene mutation status are shown in the upper section; models using age- and cytogenetics-based risk factors along with number of aCNA/cnLOH or gene mutation status are shown in the lower section.

		MI-All-AML Group (N=156)			MI-dnAML Group (N=103)
	Variables	Hazard Ratio	95% CI	p	Hazard Ratio	95% CI	p
Age + aCNA/cnLOH load + additional variable	Age ≥60 vs. <60	2.74	1.85–4.05	<0.001	2.16	1.32–3.55	<0.01
	aCNA/cnLOH ≥3 vs. <3	2.30	1.52–3.48	<0.001	2.61	1.45–4.68	<0.01
	TET2 mutated vs. wildtype	1.10	0.64–1.89	0.73	1.85	0.97–3.51	0.06
	Age ≥60 vs. <60	2.62	1.76–3.89	<0.001	2.29	1.40–3.74	<0.01
	aCNA/cnLOH ≥3 vs. <3	2.42	1.59–3.68	<0.001	2.45	1.37–4.38	<0.01
	ASXL1 mutated vs. wildtype	1.43	0.87–2.36	0.15	1.22	0.62–2.39	0.56
	Age ≥60 vs. <60	2.73	1.85–4.04	<0.001	2.35	1.45–3.82	<0.001
	aCNA/cnLOH ≥3 vs. <3	2.29	1.52–3.45	<0.001	2.37	1.34–4.19	<0.01
	DNMT3A mutated vs. wildtype	1.00	0.65–1.55	0.99	1.11	0.64–1.93	0.69
	Age ≥60 vs. <60	2.72	1.84–4.03	<0.001	2.35	1.44–3.81	<0.001
	aCNA/cnLOH ≥3 vs. <3	2.27	1.50–3.43	<0.001	2.40	1.34–4.32	<0.01
	FLT3-ITD mutated vs. wildtype	0.92	0.52–1.64	0.77	1.07	0.55–2.11	0.83
	Age ≥60 vs. <60	2.72	1.84–4.02	<0.001	2.34	1.44–3.81	<0.001
	aCNA/cnLOH ≥3 vs. <3	2.08	1.37–3.17	<0.001	2.23	1.24–4.02	<0.01
	NPM1 mutated vs. wildtype	0.62	0.36–1.09	0.09	0.79	0.43–1.43	0.42
	Age ≥60 vs. <60	2.82	1.90–4.19	<0.001	2.46	1.52–4.00	<0.001
	aCNA/cnLOH ≥3 vs. <3	1.23	0.69–2.34	0.52	1.60	0.77–3.31	0.19
	TP53 mutated vs. wildtype	3.23	1.54–6.77	<0.01	3.65	1.31–10.2	0.01
Age + cytogenetics + additional variable	Age ≥60 vs. <60	2.85	1.93–4.21	<0.001	2.40	1.48–3.90	<0.001
	Unfavorable cytogenetics vs. not	1.84	1.19–2.85	<0.01	1.66	0.96–2.85	0.06
	aCNA/cnLOH ≥4 vs. <4	1.98	1.20–3.28	<0.01	2.50	1.29–4.84	<0.01
	Age ≥60 vs. <60	2.83	1.91–4.19	<0.001	2.32	1.43–3.76	<0.001
	Unfavorable cytogenetics vs. not	1.89	1.19–2.99	<0.01	1.53	0.85–2.77	0.15
	aCNA/cnLOH ≥3 vs. <3	1.57	0.95–2.57	0.07	1.92	1.02–3.63	0.04
	Age ≥60 vs. <60	2.87	1.94–4.25	<0.001	2.51	1.55–4.06	<0.001
	Unfavorable cytogenetics vs. not	1.64	1.02–2.64	0.04	1.43	0.77–2.68	0.25
	TP53 mutated vs. wildtype	2.65	1.47–4.81	<0.001	4.08	1.56–10.7	<0.01
	Age ≥60 vs. <60	2.90	1.96–4.29	<0.001	2.25	1.38–3.68	<0.01
	Unfavorable cytogenetics vs. not	2.35	1.61–3.45	<0.001	2.20	1.28–3.79	<0.01
	TET2 mutated vs. wildtype	1.12	0.65–1.92	0.68	1.90	1.00–3.63	0.05
	Age ≥60 vs. <60	2.84	1.91–4.22	<0.001	2.43	1.50–3.96	<0.001
	Unfavorable cytogenetics vs. not	2.32	1.59–3.40	<0.001	1.97	1.17–3.34	0.01
	ASXL1 mutated vs. wildtype	1.14	0.70–1.87	0.59	1.01	0.52–1.95	0.99
	Age ≥60 vs. <60	2.89	1.96–4.28	<0.001	2.45	1.51–3.98	<0.01
	Unfavorable cytogenetics vs. not	2.37	1.61–3.48	<0.001	2.00	1.18–3.38	<0.01
	DNMT3A mutated vs. wildtype	1.12	0.72–1.74	0.62	1.19	0.68–2.05	0.54